On January 8, 2026, Piper Sandler set a price target of $16 for ARDX, implying approximately 71.4% upside from its reference level. Across the research community, Wall Street analysts have established short-term targets ranging from $8 to $16, with a consensus mean of $11.70, signalling an average potential gain of 92.1%. Over the past four weeks, ARDX has rallied by 3.6%, reflecting growing confidence in its clinical pipeline and commercial execution despite lingering questions about the timing of late-stage trial readouts.

Ardelyx reported preliminary, unaudited product revenue of approximately $378 million for full-year 2025, marking an 18% increase year-over-year. Its lead therapy, IBSRELA, generated $274 million—a 73% rise compared to 2024—with $87 million contributed in the fourth quarter. The company’s second marketed product, XPHOZAH, delivered $104 million in 2025 revenues, including $28 million in Q4, underpinning sustained adoption in its target indications.

For 2026, Ardelyx expects IBSRELA sales between $410 million and $430 million, representing at least 50% growth over 2025, while XPHOZAH is forecast to contribute $110 million to $120 million. Management reiterated its long-term ambition for IBSRELA to reach $1 billion in annual revenue by 2029, driven by expanded label opportunities and extended patent protection through December 2041. As of December 31, 2025, the company held $265 million in cash, cash equivalents and investments, deemed sufficient to fund ongoing commercial expansion and late-stage development programs.

In late 2025, Ardelyx initiated a Phase 3 clinical trial of IBSRELA in chronic idiopathic constipation, with completion expected in the second half of 2027. The company also advanced RDX10531, a next-generation NHE3 inhibitor, into early development. A recently received Notice of Allowance will extend patent coverage for both IBSRELA and XPHOZAH formulations until December 2041, reinforcing exclusivity and supporting long-term value creation for investors.